New data presented on novel orally bioavailable p300-selective degraders showing significant anti-tumor activity in preclinical models of androgen receptor (AR) positive prostate cancer SEOUL, South ...
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...
First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ...
OncoNano Medicine, Inc. (“OncoNano”) today announced a late-breaking research poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Boston, ...
SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, today announced an upcoming poster ...
– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRAS G12C inhibitors and KRAS G12 D inhibitors – SAN DIEGO, Oct. 04, 2023 ...
REDWOOD CITY, Calif., Oct. 14, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced a presentation of toripalimab data at the AACR-NCI-EORTC International ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results